Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Retatrutide vs Survodutide: they're closely matched on evidence (5.5 vs 5.5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Retatrutide and Survodutide are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Retatrutide and Survodutide have evidence — compare verdict strength side-by-side.
Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation (e.g. start 2 mg) up to 8-12 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.
once-weekly
Once-weekly subcutaneous injection (investigational only)
Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.
once-weekly
Once-weekly subcutaneous injection (investigational only)
Progressive over 24-48 weeks
By 24 weeks
By 24-36 weeks
Especially during dose escalation
Progressive over 24-46 weeks
By 48 weeks
By 16-46 weeks
Especially during dose escalation
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
N Engl J Med (2023) · Rct · n=338
Phase-2, double-blind, randomized, placebo-controlled trial in 338 adults with obesity (or overweight + a weight-related condition), once-weekly subcutaneous retatrutide 1-12 mg vs placebo for 48 weeks
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet (2023) · Rct · n=281
Phase-2, double-blind, double-dummy, placebo- and active-comparator (1.5 mg dulaglutide)-controlled trial in 281 adults with type 2 diabetes, once-weekly retatrutide 0.5-12 mg over 36 weeks
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Nat Med (2024) · Rct · n=98
Phase-2a, randomized, double-blind, placebo-controlled MASLD substudy (n=98) of the obesity trial, in participants with ≥10% liver fat, once-weekly retatrutide 1-12 mg vs placebo
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
N Engl J Med (2024) · Rct · n=293
48-week phase-2, double-blind, randomized, placebo-controlled trial in 293 adults with biopsy-confirmed MASH and fibrosis stage F1-F3, once-weekly subcutaneous survodutide 2.4/4.8/6.0 mg vs placebo with a 24-week rapid-escalation then 24-week maintenance design
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Lancet Diabetes Endocrinol (2024) · Rct · n=387
Phase-2, double-blind, randomized, placebo-controlled dose-finding trial in 387 adults with obesity (BMI ≥27) across 43 centres in 12 countries, once-weekly subcutaneous survodutide 0.6-4.8 mg vs placebo for 46 weeks
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia (2024) · Rct · n=413
Phase-2, multicentre, double-blind, randomized, placebo-controlled dose-response trial in 413 adults with type 2 diabetes, once-weekly subcutaneous survodutide across six dose groups vs placebo, with an open-label semaglutide reference arm
Both Retatrutide and Survodutide are closely matched — the best choice depends on your specific health goals.
Both Retatrutide and Survodutide score equally (68) for manage weight.
No known interactions between Retatrutide and Survodutide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.